You are here: Industry Insights > Market News > Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

2-Chlorophenothiazine

Flibanserin

its control software

iTS-CTC power cord

iTS-PSMC-24VDC-36VDC-L680-S

iTS-PSC-24VDC-36VDC-L3000-S

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

expresspharmaJanuary 28, 2021

Tag: Nordic Capital , Advanz , Cidron

Favorites

PE investor Nordic Capital has offered to buy Advanz Pharma, valuing the company at $846 million as part of a move to invest in accelerating the company’s pipeline of innovative specialty pharma products.

Under the offer, shareholders would receive a price of $17.26 per Advanz Pharma share and can also elect a non-cash alternative offer to receive unlisted shares in Cidron Aida for each Advanz Pharma share.

Previous:Unichem gets USFDA approval for Zonisamide Capsules

Next:Lilly, Vir and GSK collaborate for trial of Covid-19 therapies

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Nordic Capital makes a bid to purchase Advanz Pharma in $846 mn deal

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>